AVTX compared with LBRX: revenue, margins and what each company keeps, and the suppliers and customers both name

AVTXAvalo Therapeutics, Inc.

Mkt capRevenueRevenue

LBRXLB Pharmaceuticals Inc

Mkt capRevenueRevenue

Compare

AVTXAvalo Therapeutics, Inc.

LBRXLB Pharmaceuticals Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

AVTX: latest quarter is a loss; flow not drawable. LBRX: latest quarter not drawable.Method ›

AVTXAvalo Therapeutics, Inc.

7.25▼−0.94%· post 7.25

Mkt cap$388.8MRevenue$59,000Q4 FY25

LBRXLB Pharmaceuticals Inc

40.44▲+3.58%· post 40.45

ClosedNov 3 '26

Mkt cap$1.2BRevenue—

Compare

ClosedNov 3 '26

AVTXAvalo Therapeutics, Inc.

LBRXLB Pharmaceuticals Inc

7.25▼−0.94%post 7.25

Price

40.44▲+3.58%post 40.45

$388.8M

Mkt cap

$1.2B

Q4 FY25$59,000

Revenue

—

AVTX7.25▼−0.94%vsLBRX40.44▲+3.58%ClosedNov 3 '26

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only AVTX 5

LLYEli Lillysupplier

JNJJanssen Pharmaceutics, Inc., now Johnson & Johnson Innovative Medicine ("J&J")customer

—Leap Therapeuticsunlistedsupplier

—AlmataBiounlistedsupplier

1 more · AVTX chain ›

Shared 0

No disclosed counterparties: LBRX.

Only LBRX 0

None

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

Price

rebased to 0%

AVTX, solidLBRX, dashed